Search Results - "Bahlis, N. J."

Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? by BAHLIS, N. J, LAZARUS, H. M

“…The natural history of multiple myeloma (MM) was revolutionized by the introduction of haematopoietic stem cell transplantation to the treatment armamentarium…”
Get full text

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial by Bahlis, N J, Corso, A, Mugge, L-O, Shen, Z-X, Desjardins, P, Stoppa, A-M, Decaux, O, de Revel, T, Granell, M, Marit, G, Nahi, H, Demuynck, H, Huang, S-Y, Basu, S, Guthrie, T H, Ervin-Haynes, A, Marek, J, Chen, G, Facon, T

“…The phase 3, randomized Frontline Investigation of Revlimid and Dexamethasone Versus Standard Thalidomide (FIRST) trial investigating lenalidomide plus…”
Get full text

Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG by El Kourashy, S, Williamson, T, Chaudhry, M A, Savoie, M L, Turner, A R, Larratt, L, Storek, J, Bahlis, N J, Brown, C B, Yang, M, Quinlan, D, Geddes, M, Zacarias, N, Daly, A, Duggan, P, Stewart, D A, Russell, J A

“…Non-myeloablative (MA) and reduced intensity allo-SCT regimens are offered to older patients and/or those with comorbidities because the morbidity and…”
Get full text

MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents by Shah, M Y, Martinez-Garcia, E, Phillip, J M, Chambliss, A B, Popovic, R, Ezponda, T, Small, E C, Will, C, Phillip, M P, Neri, P, Bahlis, N J, Wirtz, D, Licht, J D

“…MMSET/WHSC1 is a histone methyltransferase (HMT) overexpressed in t(4;14)+ multiple myeloma (MM) patients, believed to be the driving factor in the…”
Get full text

Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet? by Lee, H, Duggan, P, Neri, P, Tay, J, Bahlis, N J, Jimenez-Zepeda, V H

Get full text

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma by San Miguel, Jesus F, Weisel, Katja C, Song, Kevin W, Delforge, Michel, Karlin, Lionel, Goldschmidt, Hartmut, Moreau, Philippe, Banos, Anne, Oriol, Albert, Garderet, Laurent, Cavo, Michele, Ivanova, Valentina, Alegre, Adrian, Martinez-Lopez, Joaquin, Chen, Christine, Renner, Christoph, Bahlis, Nizar Jacques, Yu, Xin, Teasdale, Terri, Sternas, Lars, Jacques, Christian, Zaki, Mohamed H, Dimopoulos, Meletios A

“…Pomalidomide is a distinct oral IMiD(®) immunomodulatory agent with direct antimyeloma, stromal-support inhibitory, and immunomodulatory effects. The pivotal,…”
Get full text

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma by Dimopoulos, Meletios A., Oriol, Albert, Nahi, Hareth, San-Miguel, Jesus, Bahlis, Nizar J., Usmani, Saad Z., Rabin, Neil, Orlowski, Robert Z., Komarnicki, Mieczyslaw, Suzuki, Kenshi, Plesner, Torben, Yoon, Sung-Soo, Ben Yehuda, Dina, Richardson, Paul G., Goldschmidt, Hartmut, Reece, Donna, Lisby, Steen, Khokhar, Nushmia Z., O’Rourke, Lisa, Chiu, Christopher, Qin, Xiang, Guckert, Mary, Ahmadi, Tahamtan, Moreau, Philippe

Get full text

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM‐3 by Lesokhin, A. M., Arnulf, B., Niesvizky, R., Mohty, M., Bahlis, N. J., Tomasson, M. H., Rodrίguez‐Otero, P., Quach, H., Raje, N. S., Iida, S., Raab, M.‐S., Czibere, A., Sullivan, S., Leip, E., Viqueira, A., Leleu, X.

Get full text

P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL by Dimopoulos, MA, Oriol, A, Nahi, H, San‐Miguel, J, Bahlis, NJ, Usmani, SZ, Rabin, N, Orlowski, RZ, Suzuki, K, Plesner, T, Yoon, SS, Ben Yehuda, D, Richardson, PG, Goldschmidt, H, Reece, D, Ahmadi, T, Qin, X, Garvin Mayo, W, Gai, X, Carey, J, Carson, R, Moreau, P

Get full text

EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA by M Solh, NJ Bahlis, NS Raje, CL Costello, B Dholaria, MY Levy, MH Tomasson, H Dube, MA Damore, HK Lon, C Basu, A Skoura, EM Chan, S Trudel, A Jakubowiak, MP Chu, C Gasparetto, A Dalovisio, M Sebag, AM Lesokhin

“…Objectives: Elranatamab (PF-06863135) is a humanized bispecific monoclonal antibody (IgG2a) that targets BCMA, a member of the tumor necrosis factor receptor…”
Get full text

Ascorbic acid enhances arsenic trioxide–induced cytotoxicity in multiple myeloma cells by Grad, Jennifer M., Bahlis, Nizar J., Reis, Isildinha, Oshiro, Marc M., Dalton, William S., Boise, Lawrence H.

“…Multiple myeloma (MM) is a clonal B-cell malignancy characterized by slow-growing plasma cells in the bone marrow (BM). Patients with MM typically respond to…”
Get full text

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma by Dimopoulos, Meletios A, Oriol, Albert, Nahi, Hareth, San-Miguel, Jesus, Bahlis, Nizar J, Usmani, Saad Z, Rabin, Neil, Orlowski, Robert Z, Komarnicki, Mieczyslaw, Suzuki, Kenshi, Plesner, Torben, Yoon, Sung-Soo, Ben Yehuda, Dina, Richardson, Paul G, Goldschmidt, Hartmut, Reece, Donna, Lisby, Steen, Khokhar, Nushmia Z, O’Rourke, Lisa, Chiu, Christopher, Qin, Xiang, Guckert, Mary, Ahmadi, Tahamtan, Moreau, Philippe

“…The addition of daratumumab to lenalidomide and dexamethasone resulted in superior response rate and progression-free survival, as compared with lenalidomide…”
Get full text

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma by Moreau, Philippe, Masszi, Tamás, Grzasko, Norbert, Bahlis, Nizar J, Hansson, Markus, Pour, Ludek, Sandhu, Irwindeep, Ganly, Peter, Baker, Bartrum W, Jackson, Sharon R, Stoppa, Anne-Marie, Simpson, David R, Gimsing, Peter, Palumbo, Antonio, Garderet, Laurent, Cavo, Michele, Kumar, Shaji, Touzeau, Cyrille, Buadi, Francis K, Laubach, Jacob P, Berg, Deborah T, Lin, Jianchang, Di Bacco, Alessandra, Hui, Ai-Min, van de Velde, Helgi, Richardson, Paul G

“…The addition of the oral proteasome inhibitor ixazomib to a regimen of lenalidomide plus dexamethasone led to a significant prolongation of progression-free…”
Get full text

Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals by KHARFAN-DABAJA, Mohamed A, AYALA, Ernesto, LINDNER, Inna, CEJAS, Pedro J, BAHLIS, Nizar J, KOLONIAS, Despina, CARLSON, Louise M, LEE, Kelvin P

“…Ex vivo differentiation of myeloid leukemic blasts into dendritic cells (DCs) holds significant promise for use as cellular vaccines, as they may present a…”
Get full text

Minimal residual disease by Lee, H, Tay, J, Jimenez-Zepeda, V H, Neri, P, Duggan, P, Bahlis, N J

Get full text

Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide by Delforge, Michel, Minuk, Leonard, Eisenmann, Jean-Claude, Arnulf, Bertrand, Canepa, Letizia, Fragasso, Alberto, Leyvraz, Serge, Langer, Christian, Ezaydi, Yousef, Vogl, Dan T, Giraldo-Castellano, Pilar, Yoon, Sung-Soo, Zarnitsky, Charles, Escoffre-Barbe, Martine, Lemieux, Bernard, Song, Kevin, Bahlis, Nizar Jacques, Guo, Shien, Monzini, Mara Silva, Ervin-Haynes, Annette, Houck, Vanessa, Facon, Thierry

“…We compared the health-related quality-of-life of patients with newly diagnosed multiple myeloma aged over 65 years or transplant-ineligible in the pivotal,…”
Get full text

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone by Dimopoulos, Meletios A, Weisel, Katja C, Song, Kevin W, Delforge, Michel, Karlin, Lionel, Goldschmidt, Hartmut, Moreau, Philippe, Banos, Anne, Oriol, Albert, Garderet, Laurent, Cavo, Michele, Ivanova, Valentina, Alegre, Adrian, Martinez-Lopez, Joaquin, Chen, Christine, Spencer, Andrew, Knop, Stefan, Bahlis, Nizar J, Renner, Christoph, Yu, Xin, Hong, Kevin, Sternas, Lars, Jacques, Christian, Zaki, Mohamed H, San Miguel, Jesus F

“…Patients with refractory or relapsed and refractory multiple myeloma who no longer receive benefit from novel agents have limited treatment options and short…”
Get full text

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial by Lonial, Sagar, Prof, Weiss, Brendan M, Prof, Usmani, Saad Z, Prof, Singhal, Seema, Prof, Chari, Ajai, Prof, Bahlis, Nizar J, Prof, Belch, Andrew, Prof, Krishnan, Amrita, Prof, Vescio, Robert A, Prof, Mateos, Maria Victoria, Prof, Mazumder, Amitabha, Prof, Orlowski, Robert Z, Prof, Sutherland, Heather J, Prof, Bladé, Joan, Prof, Scott, Emma C, Prof, Oriol, Albert, MD, Berdeja, Jesus, MD, Gharibo, Mecide, Prof, Stevens, Don A, MD, LeBlanc, Richard, Prof, Sebag, Michael, Prof, Callander, Natalie, Prof, Jakubowiak, Andrzej, Prof, White, Darrell, Prof, de la Rubia, Javier, Prof, Richardson, Paul G, Prof, Lisby, Steen, MD, Feng, Huaibao, PhD, Uhlar, Clarissa M, PhD, Khan, Imran, MD, Ahmadi, Tahamtan, MD, Voorhees, Peter M, Prof

“…Summary Background New treatment options are needed for patients with multiple myeloma that is refractory to proteasome inhibitors and immunomodulatory drugs…”
Get full text

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma by Usmani, Saad Z., Weiss, Brendan M., Plesner, Torben, Bahlis, Nizar J., Belch, Andrew, Lonial, Sagar, Lokhorst, Henk M., Voorhees, Peter M., Richardson, Paul G., Chari, Ajai, Sasser, A.Kate, Axel, Amy, Feng, Huaibao, Uhlar, Clarissa M., Wang, Jianping, Khan, Imran, Ahmadi, Tahamtan, Nahi, Hareth

“…The efficacy and favorable safety profile of daratumumab monotherapy in multiple myeloma (MM) was previously reported. Here, we present an updated pooled…”
Get full text

New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma by Neri, Paola, Bahlis, Nizar J, Lonial, Sagar

“…Multiple myeloma is a B-cell malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Although new therapeutic options…”
Get full text